Cilostazol
Function and Efficacy
This product inhibits the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the cAMP concentration in platelets and smooth muscle, exerting antiplatelet and vasodilatory effects. This product inhibits the initial and secondary aggregation and release reactions of platelets induced by ADP, adrenaline, collagen and arachidonic acid, and is dose-dependent. Oral administration of 100 mg of cilostazol is 7 to 78 times more effective than the corresponding amount of aspirin in inhibiting platelet aggregation in vitro (aspirin is ineffective against initial platelet aggregation). This product does not interfere with the synthesis of vascular protective prostacyclin by endothelial cells. For patients with chronic arterial occlusion, the use of volume volumography shows that this product can increase tissue blood flow in the foot and gastrocnemius muscles, increase the blood pressure index of the lower limbs, increase skin blood flow and skin temperature of the limbs, and improve intermittent claudication.
Ingredients
The main ingredient of this product is cilostazol, and its chemical name is 6-[4-(1-cyclohexyl-1H-tetrazolyl-5-yl)-butoxy]-3,4-dihydro-2(1H)quinolone.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| CilostazolIngredients |
It exerts antiplatelet and vasodilator effects by inhibiting the activity of phosphodiesterase in platelets and vascular smooth muscle, increasing the cAMP concentration in platelets and smooth muscle; inhibiting the initial and secondary platelet aggregation and release reactions induced by ADP, adrenaline, collagen and arachidonic acid; not interfering with the synthesis of vascular protective prostacyclin by vascular endothelial cells; for patients with chronic arterial occlusion, it can increase tissue blood flow in the foot and gastrocnemius muscles, increase the lower limb blood pressure index, increase skin blood flow and skin temperature of the limbs, and improve intermittent claudication. More |
73963-72-1 | 29 |
Indication
It can inhibit platelet aggregation and has antithrombotic effect. It is used to treat local diseases such as chronic arterial occlusive ulcers, pain and cold sensation.
Usage and Dosage
Oral: Adults, 50-100 mg at a time, twice a day. For young patients, the dose can be increased appropriately if necessary based on symptoms.
Adverse Reactions
1. The main adverse reactions are headache, dizziness and palpitations caused by vasodilation, and some patients may have high blood pressure. 2. The second most common adverse reactions are abdominal distension, nausea, vomiting, stomach discomfort, abdominal pain and other digestive tract symptoms. 3. A small number of patients have abnormal liver function, frequent urination, abnormal urea nitrogen, creatinine and uric acid values after taking the drug. 4. Allergic symptoms include rash and itching. 5. Other reports include occasional leukopenia, subcutaneous hemorrhage, gastrointestinal bleeding, epistaxis, hematuria, fundus hemorrhage, etc.
Precautions
Patients with bleeding disorders (such as hemophilia, capillary fragility, active peptic ulcer, hematuria, hemoptysis, functional uterine bleeding, etc. or other bleeding tendencies).
Drug Interactions
Prostaglandin E1 can act synergistically with this product to increase intracellular cyclic adenosine monophosphate and enhance therapeutic efficacy.
Storage
Light-proof, airtight
Manufacturer
Jiangsu Tasly DIYI Pharmaceutical Co., Ltd.
-
Founded in:
1999-03-24 -
Address:
No. 168, Chaoyang West Road, Qingpu Industrial Park, Huai'an City -
Tax NO.:
91320800139432975C -
Registered Funds:
66.86 million yuan -
Website:
-
Email: